Loading…
CBD Social sold unapproved CBD products on its website with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19, violating section 505(a) of the Federal Food, Drug, and Cosmetic Act by marketing unapproved new drugs. The products were also misbranded under section 502 of the FD&C Act. The FDA took this enforcement action during the COVID-19 public health emergency to protect consumers from unauthorized products making disease claims without FDA approval.